510(k) Report

510(k) · Cleared

Recalled · Class II · 2012

Sofia Analyzer and Influenza a+B Fia

K112177510(k) TraditionalCleared Oct 24, 201188-day reviewClass II21 CFR 866.3328Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Quidel Corp. · PSZ Devices Detecting Influenza A, B, And C Virus Antigens

Cleared on Oct 24, 2011 after an 88-day review. The FDA summary names its predicate without a number. 8 later devices descend from it. It has been recalled once.

Decided
Oct 24, 2011
Review
88 days
Class
Class II
Product code
PSZ
Recalls
1
Predicates
0

8 later devices descend from it, 3 citing it directly.

Descendants, by year cleared 2017: 2 descendants cleared2016: 1 descendant cleared2013: 1 descendant cleared2014: 1 descendant cleared2018: 1 descendant cleared2026: 1 descendant cleared2020: 1 descendant cleared2010201520202025
  1. This deviceK112177 Sofia Analyzer and Influenza a+B FiaQuidel Corp. · 2011
  2. Descendant · cites it directly · 4 of its ownK153012 Sofia Influenza A+B FIAQuidel Corporation · 2016
  3. Descendant · cites it directly · 3 of its ownK162438 Sofia Influenza A+B FIA on Sofia 2Quidel Corporation · 2017 · Recalled
  4. Descendant · cites it directly · 2 of its ownK123793 Sofia Strep a FiaQuidel Corporation · 2013
  5. Descendant · 2 generations on · 1 of its ownK180288 QuickVue Influenza A+BQuidel Corporation · 2018
  6. Descendant · 2 generations on · 1 of its ownK141775 Sofia (R) Strep a+ FiaQuidel Corporation · 2014 · Recalled

Showing 5 of 8 descendants. See all descendants

Descendants cleared per year

2013: 12014: 12016: 12017: 22018: 12020: 12026: 1
2013high 2 (2017) · low 0 (2015)2026

Most influential descendants

Showing 5 of 8 · See all
  • K153012Sofia Influenza A+B FIAQuidel Corporation · 2016 · cites it directly4descendants
  • K162438Sofia Influenza A+B FIA on Sofia 2Quidel Corporation · 2017 · cites it directly3descendants
  • K123793Sofia Strep a FiaQuidel Corporation · 2013 · cites it directly2descendants
  • K180288QuickVue Influenza A+BQuidel Corporation · 2018 · 2 generations on1descendant
  • K141775Sofia (R) Strep a+ FiaQuidel Corporation · 2014 · 2 generations on1descendant
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K112177Sofia Analyzer and Influenza a+B FiaQuidel Corp.2011—
+1K153012Sofia Influenza A+B FIAQuidel Corporation2016—
+1K162438Sofia Influenza A+B FIA on Sofia 2Quidel Corporation20171
+1K123793Sofia Strep a FiaQuidel Corporation2013—
+2K180288QuickVue Influenza A+BQuidel Corporation2018—
+2K141775Sofia (R) Strep a+ FiaQuidel Corporation20141

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201310
201410
201610
201720
201810
202010
202610
FIG. 1 — Lineage of K112177, 2011–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PSZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PSZ device

  1. #1 K252283 Nano-Check Influenza A+B Testscore 14.9 · 15 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—3M Rapid Detection Flu A+B Reader and Test
Named without a submission number
—
*—QuickVue Influenza A+B Test
Named without a submission number
—

What descends from it? (8)

3 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K153012Sofia Influenza A+B FIAQuidel Corporation20164
K162438Sofia Influenza A+B FIA on Sofia 2Quidel Corporation20173
K123793Sofia Strep a FiaQuidel Corporation20132

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Dec 3, 2012Class IIZ-0819-2013Nonconforming Material/ComponentQuidel Corporation has initiated a voluntary recall of specific lots of the Sofia Influenza A+B FIA kits because of false positive results which may lead to misdiagnosis.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K153012 (Quidel Corporation, 2016) has gone furthest, with 4 descendants of its own.

How does its category compare?

All PSZ devices

PSZ Devices Detecting Influenza A, B, And C Virus Antigens: FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.

FDA decisions per year · PSZ

2in 2025

2007: 22008: 12009: 72010: 52011: 32012: 22013: 82014: 12015: 42016: 32017: 32018: 52020: 22023: 22025: 22026 (partial year): 2
2007high 8 (2013) · low 0 (2019)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PSZ

28in 2018

2009: 20 days median2010: 29 days median2011: 80 days median2013: 28 days median2015: 27 days median2016: 29 days median2017: 200 days median2018: 28 days median
2007high 200 (2017) · low 20 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PSZ

1in 2022

2020: 12022: 1
2007high 1 (2020) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PSZ

60in 2025

2018: 12019: 12020: 52021: 422022: 102023: 122024: 162025: 60
2007high 60 (2025) · low 0 (2007)2025

MAUDE reports naming product code PSZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
200972000
201052900
201138000
20122—00
201382800
20141—00
201542700
201632900
2017320000
201852801
20190—01
20202—15
20210—042
20220—110
20232—012
20240—016
20252—060
20262—0—

What is it indicated for?

The Sofia Influenza A+B FIA employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens taken directly from symptomatic patients. This qualitative test is intended for use as an aid in the rapid differential diagnosis of acute influenza A and influenza B viral infections. The test is not intended to detect influenza C antigens. A negative test…

Read the full statement (255 words)

The Sofia Influenza A+B FIA employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens taken directly from symptomatic patients. This qualitative test is intended for use as an aid in the rapid differential diagnosis of acute influenza A and influenza B viral infections. The test is not intended to detect influenza C antigens. A negative test is presumptive and it is recommended these results be confirmed by virus culture or an FDA-cleared influenza A and B molecular assay. Negative results do not preclude influenza virus infections and should not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.

Performance characteristics for influenza A and B were established during February through March 2011 when influenza viruses A/California/7/2009 (2009 Hi11\1), A/PerthI16I2009 (1-3N\2), and BlBrisbane/60/2008 (Victoria-Like) were the predominant influenza viruses in circulation according to the Morbidity and Mortality Weekly Report from the CDC entitled "Update: Influenza Activity--United States, 2010-2011 Season, and Composition of the 2011-2012 Influenza Vaccine". Performance characteristics may vary against other emerging influenza viruses.

If infection with a novel influenza virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Virus culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K112177: Sofia Analyzer and Influenza a+B Fia.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K112177

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026